BIA-ALCL diagnosis on CytoLyt fixed ThinPrep, cell block and immunohistochemistry

Sedef Everest1, Renu Virk1, Abel Gonzalez1

  • 1Department of Pathology and Cell Biology, Columbia University, New York City, New York, USA.

Diagnostic Cytopathology
|October 8, 2021
PubMed

Insights

This study details the initial diagnosis of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) using ThinPrep cytology. It highlights key cytomorphological features and immunohistochemistry findings for accurate BIA-ALCL detection.

Area of Science:

  • Oncology
  • Hematopathology
  • Cytopathology

Background:

  • Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a rare T-cell lymphoma linked to breast implants, especially textured ones.
  • Current diagnostic guidelines emphasize cytopathology, followed by CD30 immunohistochemistry (IHC) and flow cytometry (FC) for T-cell clonality.
  • Existing literature on BIA-ALCL cytopathology primarily focuses on cytospins and smears, with limited data on ThinPrep preparations.

Observation:

  • This case report describes the diagnosis of BIA-ALCL using ThinPrep and cell block preparations processed with CytoLyt.
  • Microscopic examination of ThinPrep slides revealed numerous large, atypical lymphoid cells with irregular nuclei and prominent nucleoli.
  • These cells were found in a background of inflammatory cells, macrophages, and granular debris.

Findings:

  • Immunohistochemistry (IHC) confirmed TIA-1 and CD30 reactivity, along with other T-cell markers, in cells preserved in CytoLyt solution.
  • The study details the specific antibodies utilized for IHC analysis in the BIA-ALCL diagnosis.
  • Potential ThinPrep artifacts, such as cell size reduction and artifactual lymphoid aggregation, were noted.

Implications:

  • This report validates ThinPrep and cell block methods for BIA-ALCL diagnosis, expanding cytopathological evaluation techniques.
  • Accurate identification of BIA-ALCL requires careful consideration of cytomorphological features and IHC results.
  • Pathologists must be aware of ThinPrep-induced cellular alterations to avoid misdiagnosis in both benign and reactive conditions.

Related Concept Videos